The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect tumours from attack by the immune system. Injections of the mRNA-4359 vaccine have started in the UK at Imperial College Healthcare NHS Trust in the Mobilize study. Source: Pharmaphorum 9/2/2024